



THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

# Comparison of Different Phenotypic Approaches to Screen and Detect *mecC*-Harboring Methicillin-Resistant *Staphylococcus aureus*

### Citation for published version:

Kriegeskorte, A, Idelevich, EA, Schlattmann, A, Layer, F, Strommenger, B, Denis, O, Paterson, GK, Holmes, MA, Werner, G & Becker, K 2017, 'Comparison of Different Phenotypic Approaches to Screen and Detect *mecC*-Harboring Methicillin-Resistant *Staphylococcus aureus*', *Journal of Clinical Microbiology*.  
<https://doi.org/10.1128/JCM.00826-17>

### Digital Object Identifier (DOI):

[10.1128/JCM.00826-17](https://doi.org/10.1128/JCM.00826-17)

### Link:

[Link to publication record in Edinburgh Research Explorer](#)

### Document Version:

Publisher's PDF, also known as Version of record

### Published In:

Journal of Clinical Microbiology

### General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

### Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



1 Comparison of Different Phenotypic Approaches to Screen and Detect *mecC*-Harboring  
2 Methicillin-Resistant *Staphylococcus aureus*

3

4

5 André Kriegeskorte,<sup>a\*</sup> Evgeny A. Idelevich,<sup>a</sup> Andreas Schlattmann,<sup>a</sup> Franziska Layer,<sup>b</sup> Birgit

6 Strommenger,<sup>b</sup> Olivier Denis,<sup>c</sup> Gavin K. Paterson,<sup>d</sup> Mark A. Holmes,<sup>e</sup> Guido Werner,<sup>f</sup>

7 Karsten Becker<sup>a#</sup>

8

9 Institute of Medical Microbiology, University Hospital Münster, Münster, Germany<sup>a</sup>;

10 Robert-Koch-Institute, Berlin, Germany<sup>b</sup>;

11 Laboratoire de Microbiologie, Hôpital Erasme, Université libre de Bruxelles, Brussels,

12 Belgium<sup>c</sup>;

13 Royal (Dick) School of Veterinary Studies, University of Edinburgh, Midlothian, United

14 Kingdom<sup>d</sup>;

15 Department of Veterinary Medicine, University of Cambridge, Cambridge, United

16 Kingdom<sup>e</sup>;

17 Robert-Koch-Institute, Wernigerode Branch, Wernigerode, Germany<sup>f</sup>

18

19 Running Head: Phenotypic Approaches to Detect *mecC* MRSA

20

21 #Address correspondence to Karsten Becker, kbecker@uni-muenster.de

22

23 \*Present address: GSK Vaccines GmbH, Marburg, Germany

24 A.K. and E.A.I. contributed equally to this work

25

26 **Abstract**

27 Similar to *mecA*, *mecC* confers resistance against beta-lactams, leading to the phenotype of a  
28 methicillin-resistant *Staphylococcus aureus* (MRSA). However, *mecC*-harboring MRSA pose  
29 special difficulties in their detection. The aim of this study was to assess and compare  
30 different phenotypic systems for screening, identification, and susceptibility testing of *mecC*-  
31 positive MRSA isolates. A well-characterized collection of *mecC*-positive *S. aureus* isolates  
32 (n = 111) was used for evaluation. Routinely used approaches were studied to determine their  
33 suitability to correctly identify *mecC*-harboring MRSA including three (semi-)automated  
34 antimicrobial susceptibility testing (AST) systems and five selective chromogenic agar plates.  
35 Additionally, a cefoxitin disk diffusion test and an oxacillin broth microdilution assay were  
36 examined. All *mecC*-harboring MRSA isolates were able to grow on all chromogenic MRSA  
37 screening plates tested. Detection of these isolates in AST systems based on cefoxitin and/or  
38 oxacillin testing yielded overall positive agreement with the *mecC* genotype of 97.3 %  
39 (MicroScan WalkAway™, Siemens), 91.9 % (Vitek 2®, bioMérieux), and 64.9 %  
40 (Phoenix™, BD). The phenotypic resistance pattern most frequently observed by AST  
41 devices was “cefoxitin resistance/oxacillin susceptibility”, ranging from 54.1 % (Phoenix)  
42 over 83.8 % (Vitek 2) to 92.8 % (WalkAway). The cefoxitin disk diffusion and oxacillin  
43 broth microdilution assays categorized 100 % and 61.3 % of isolates to be MRSA,  
44 respectively. The chromogenic media tested confirmed their suitability to reliably screen for  
45 *mecC*-harboring MRSA. The AST systems showed false-negative results with varying  
46 numbers, misidentifying *mecC* MRSA as methicillin susceptible *S. aureus*. This study  
47 underlines cefoxitin’s status as the superior surrogate *mecC* MRSA marker.

48

49 **Introduction**

50 The still worrying occurrence of methicillin-resistant *Staphylococcus aureus* (MRSA) in  
51 many parts of the world poses a major challenge to health care systems by increasing the  
52 burden of disease. Rapid and effective MRSA identification and susceptibility testing is  
53 paramount to prevent further dissemination and to adapt antimicrobial treatment. In 2011, a  
54 novel PBP2a-encoding *mecA* homologue designated *mecC* (originally *mecA<sub>LGA251</sub>*) has been  
55 reported with homologies on the nucleotide and protein level of only 70 % and 63 %,  
56 respectively [1, 2]. Later on, *mecC* has been confirmed as the genetic determinant that  
57 confers methicillin resistance in *S. aureus* for those isolates [3]. Farm and wildlife animals  
58 have been revealed as reservoirs for *mecC* MRSA [4, 5], and the zoonotic potential of these  
59 livestock-associated MRSA has been shown [6, 7, 8].

60 The limited homology of *mecC* to *mecA* and their respective proteins led to major diagnostic  
61 challenges in identification and susceptibility testing of *mecC*-harboring MRSA [9]. In  
62 addition to obvious but easily resolved difficulties in targeting the divergent *mecC* nucleotide  
63 sequence by DNA-based diagnostic tests [10, 11], phenotypic approaches exhibited  
64 considerable difficulties due to comparatively low oxacillin MICs [1, 7, 8] which may be  
65 caused by differences in the *mecA* and *mecC* promoters [3]. Moreover, low homology  
66 between the encoded PBP2a proteins is the reason for the failure of existing PBP2a  
67 agglutination tests to detect *mecC*-positive isolates [5, 7, 8]

68 In this study, we compared several routinely applied diagnostic approaches in their capability  
69 to identify *mecC*-harboring MRSA from a comprehensive, heterogeneous, and representative  
70 collection. In detail, we compared (i) three (semi-)automated susceptibility testing (AST)  
71 systems, (ii) five selective chromogenic agar plates (MRSA screening plates), (iii) a cefoxitin  
72 disk diffusion test, and (iv) an oxacillin broth microdilution.

73

74 **Results**

75

76 **Applicability of AST systems to detect *mecC*-positive isolates**

77 Analyzing resistance towards cefoxitin and oxacillin by AST systems, different susceptibility  
78 patterns were observed. For all systems, the most frequently detected pattern was the  
79 combination of the categorization “cefoxitin-resistant, but oxacillin-susceptible”, ranging  
80 from 54.1 % (Phoenix) over 83.8 % (Vitek 2) to 92.8 % (WalkAway) of all tested isolates  
81 (Table 1). In the WalkAway system, three isolates (2.7 %) were categorized cefoxitin- and  
82 oxacillin-susceptible, whereas in the Vitek 2 and the Phoenix system, 9 isolates (8.1 %) and  
83 39 isolates (35.1 %), respectively, were categorized susceptible to both. One isolate was  
84 categorized as cefoxitin-susceptible and oxacillin-resistant by the Phoenix system.

85 The MIC<sub>90</sub> values for oxacillin were  $\geq 2$   $\mu\text{g/ml}$  (Phoenix), 2  $\mu\text{g/ml}$  (MicroScan), and 2  $\mu\text{g/ml}$   
86 (Vitek 2). The MIC<sub>90</sub> values for cefoxitin were  $> 8$   $\mu\text{g/ml}$  (Phoenix) and  $> 4$   $\mu\text{g/ml}$   
87 (WalkAway); the Vitek 2 detected 91.9 % of isolates as resistant to cefoxitin without  
88 reporting an MIC value. Less than 10 % of isolates were tested resistant to both cefoxitin and  
89 oxacillin (Phoenix: 9.9 %; MicroScan: 4.5 %; Vitek 2: 8.1 %).

90

91 **Applicability of chromogenic MRSA screening plates for detection of *mecC*-positive  
92 isolates**

93 The vast majority of isolates showed typical growth on all tested cefoxitin-containing  
94 chromogenic MRSA screening plates. Reduced growth, i.e. smaller colonies, but with  
95 characteristic MRSA-indicating color, was observed for a small fraction of isolates (Table 2).  
96 Oxoid Brilliance™ MRSA 2 plates showed a mixed phenotypic appearance with blue  
97 (presumptive for MRSA) and white colonies for all isolates.

98 Additionally, a subset of nine isolates and positive control *S. aureus* USA 300, tested in  
99 triplicate, showed growth on screening plates from four manufacturers using an inoculum of  
100 100 µl from of a 10<sup>-5</sup> dilution of a 0.5 McFarland standard suspension (approximately 100  
101 cfu/plate). MRSA Select™ agar plates (Bio-Rad) were not tested in this additional  
102 experiment due to supply unavailability. Negative control *S. aureus* ATCC 29213 exhibited  
103 no growth on chromogenic agar plates.

104

#### 105 **Applicability of cefoxitin disk diffusion and oxacillin broth microdilution test for** 106 **detection of *mecC*-positive isolates**

107 The cefoxitin disk diffusion test detected *mecC*-encoded methicillin resistance in 111/111  
108 isolates, i.e. 100 %. The oxacillin broth microdilution resulted in a categorization of 43  
109 susceptible (38.7 %) and 68 resistant (61.3 %) isolates.

110

111

#### 112 **Discussion**

113 The occurrence of *mecC*-harboring MRSA has been described in several European countries  
114 in humans, companion animals, and livestock [14]. While the overall prevalence of these  
115 isolates seems to be low, it has been suspected that *mecC* prevalence might be underestimated  
116 because of its misidentification as methicillin-susceptible *S. aureus* (MSSA) due to its  
117 borderline resistant phenotype. Additionally, negative results in MRSA PCR and  
118 agglutination assays if only the *mecA* gene, i.e. PBP2a is targeted, hamper *mecC* MRSA  
119 detection efforts. Furthermore, it has been shown that the prevalence of *mecC*-positive  
120 *S. aureus* isolates increased at least in Denmark and that *mecC* MRSA isolates are also  
121 capable to cause infections in humans [4]. A reliable detection of these isolates is important  
122 to ensure both an adequate treatment of *mecC* MRSA infections and the use of the same

123 prevention measures as already established for *mecA* MRSA. This study revealed that all  
124 chromogenic media and the cefoxitin disk diffusion test were able to categorize all *mecC*-  
125 positive MRSA properly. Additionally, we were able to show for a subset of strains that  
126 inocula as low as approximately 100 cfu per plate result in growth on chromogenic media,  
127 indicating that a recovery from clinical swab samples with low MRSA loads can likely be  
128 achieved. However, these findings are limited because they could mimic the usual clinical  
129 specimen as encountered in the laboratory only partially. To varying degrees, all three AST  
130 systems displayed limitations in the ability to detect *mecC* MRSA. While the detection rate of  
131 WalkAway (97.3 %) was also high, the Vitek 2 (91.9 %) and particularly the Phoenix system  
132 (64.9 %) showed considerably lower rates. A study by Cartwright *et al.* showed a detection  
133 rate of 88.7 % (n = 62 *mecC* MRSA) for the cefoxitin-resistant/oxacillin-susceptible pattern  
134 using the Vitek 2 [15]; similarly, this AST device detected this pattern in 83.8 % of the tested  
135 isolates in our study. The oxacillin broth microdilution performed poorly, showing a  
136 detection rate of only 61.3 %. This is in accordance with previous studies [16].

137 In conclusion, automated systems may fail to detect *mecC*-encoded methicillin resistance,  
138 while all chromogenic screening media displayed colonies presumptive for MRSA growth. In  
139 comparison to oxacillin, cefoxitin was confirmed as superior surrogate marker to detect  
140 *mecC*-harboring MRSA isolates. Discrepancies between positive screening results based on  
141 the use of chromogenic media and categorization as methicillin-susceptible by AST systems  
142 should be verified by molecular assays or disk diffusion.

143

144

## 145 **Material and Methods**

146 A large set of *mecC*-harboring MRSA isolates (n = 111) from human and animal specimens  
147 isolated in Germany, the United Kingdom, and Belgium were included in the study. All

148 isolates were confirmed as *mecC*-positive by PCR [12] and characterized by *spa*-typing  
149 (t843, n = 51; t6292, n = 13; t1736, n = 6; t1535, n = 4; t3391, n = 3; t978, t9165, t742, t6902,  
150 t6521, t6220, t5930, t1773, t11706, n = 2 each; t9910, t9738, t9280, t9123, t8842, t7914,  
151 t7603, t7189, t6300, t524, t13233, t1207, t11702, t11290, t11120 and not typeable, n = 1  
152 each). Isolates were of human (n = 80), unknown (n = 24), bovine/bulk milk (n = 4), sheep (n  
153 = 2), and environmental (n = 1) origin. No copy isolates were included.

154 Selective chromogenic agar plates (1. Oxoid: Brilliance™ MRSA 2; 2. bioMérieux:  
155 chromID® MRSA; 3. BD: BBL™ CHROMagar® MRSA II; 4. Bio-Rad: MRSA Select™; 5.  
156 MAST Diagnostica: CHROMagar™ MRSA) were inoculated with a single colony from  
157 overnight blood agar plate cultures. To simulate potentially low inocula of clinical specimens,  
158 nine isolates with different *spa*-types (t843, t978, t1207, t1535, t1736, t391, t5930, t6292 and  
159 t6902) were each adjusted to 0.5 McFarland standard turbidity and serial dilutions with the  
160 final dilution factor of 10<sup>5</sup> were prepared. Subsequently, 100 µl of the final dilutions were  
161 used to inoculate all chromogenic media (except MRSA Select™ from Bio-Rad due to  
162 supply constraints) and blood agar plates for growth control in triplicate. *S. aureus* strains  
163 USA300 and ATCC29213 were used as positive and negative controls, respectively. Growth  
164 was evaluated after 24 h and 48 h. Automated systems were inoculated from the same plates  
165 as chromogenic media. Automated systems for susceptibility testing were used according to  
166 the manufacturers' recommendations, i.e. the BD Phoenix™ (Becton Dickinson, Heidelberg,  
167 Germany) was executed with the test panel PMIC-72, the Vitek 2® (bioMérieux, Marcy  
168 l'Etoile, France) with the test panel AST P580, and the MicroScan WalkAway® 96 plus  
169 (Siemens Healthcare Diagnostics, Eschborn, Germany) with the test panel Pos MIC 28.  
170 Cefoxitin disk diffusion assays (Cefoxitin discs, 30 µg, bestbion dx, Cologne, Germany) were  
171 performed according to EUCAST and using *S. aureus* ATCC 29213 as control. The  
172 EUCAST guidelines (version 7.0, valid from 01.01.2017: Inhibition zone of <22 mm,



173 resistant) and CLSI criteria (M100-S27, Twenty-seventh Edition, January 2017: inhibition  
174 zone of  $\leq 21$  mm, resistant) were followed in the interpretation of the results.

175 Oxacillin (Sigma-Aldrich, Taufkirchen, Germany) susceptibility was determined by broth  
176 microdilution, using a final inoculum of approximately  $5 \times 10^5$  CFU/ml and *S. aureus*  
177 ATCC 29213 as quality control. MICs were interpreted according to EUCAST guidelines  
178 (version 7.0, valid from 01.01.2017: MIC  $> 2$   $\mu\text{g/ml}$ ) and CLSI criteria (M100-S27, Twenty-  
179 seventh Edition, January 2017: MIC  $\geq 4$   $\mu\text{g/ml}$ ).

180

### 181 **Acknowledgements**

182 We are grateful to B. Grünastel and F. Erdmann for expert technical assistance. This work  
183 was supported in part by grants from the German Ministry for Education and Research  
184 (BMBF 03ZZ0802H (K.B.) and 03ZZ0805B (K.B.) and performed under the auspices of the  
185 Paul Ehrlich Gesellschaft für Chemotherapie, Section “Basics” and its working groups  
186 “Susceptibility testing and resistance” (G.W.) and “Staphylococcal infections” (K.B.). The  
187 Instruments Phoenix™ (BD) and MicroScan WalkAway® (Siemens) were provided free of  
188 charge during the study. The authors declare no conflict of interest.

189 **References**

190

- 191 1. García-Álvarez L, Holden MTG, Lindsay H, Webb CR, Brown DFJ, Curran MD,  
192 Walpole E, Brooks K, Pickard DJ, Teale C, Parkhill J, Bentley SD, Edwards GF, Girvan  
193 EK, Kearns AM, Pichon B, Hill RLR, Larsen AR, Skov RL, Peacock SJ, Maskell DJ,  
194 Holmes MA. 2011. Methicillin-resistant *Staphylococcus aureus* with a novel *mecA*  
195 homologue in human and bovine populations in the UK and Denmark: a descriptive  
196 study. *Lancet Infect Dis* 11:595–603.
- 197 2. Shore AC, Deasy EC, Slickers P, Brennan G, O’Connell B, Monecke S, Ehricht R,  
198 Coleman DC. 2011. Detection of staphylococcal cassette chromosome mectype XI  
199 encoding highly divergent *mecA*, *mecI*, *mecR1*, *blaZ* and *ccr* genes in human clinical  
200 clonal complex 130 methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents*  
201 *Chemother* 55: 3765–3773.
- 202 3. Ballhausen B, Kriegeskorte A, Schleimer N, Peters G, Becker K. 2014. The *mecA*  
203 homolog *mecC* confers resistance against beta-lactams in *Staphylococcus aureus*  
204 irrespective of the genetic strain background. *Antimicrob Agents Chemother* 58(7):3791-  
205 3798.
- 206 4. Petersen A, Stegger M, Heltberg O, Christensen J, Zeuthen A, Knudsen LK, Urth T,  
207 Sorum M, Schouls L, Larsen J, Skov R, Larsen AR. 2013. Epidemiology of methicillin-  
208 resistant *Staphylococcus aureus* carrying the novel *mecC* gene in Denmark corroborates  
209 a zoonotic reservoir with transmission to humans. *Clin Microbiol Infect* 19(1):E16 - E22.
- 210 5. Paterson GK, Morgan FJ, Harrison EM, Peacock SJ, Parkhill J, Zadoks RN, Holmes  
211 MA. 2014. Prevalence and properties of *mecC* methicillin-resistant *Staphylococcus*  
212 *aureus* (MRSA) in bovine bulk tank milk in Great Britain. *J Antimicrob Chemother*  
213 69(3):598-602.

- 214 6. Kerschner H, Harrison EM, Hartl R, Holmes MA, Apfalter P. 2015. First report of *mecC*  
215 MRSA in human samples from Austria: molecular characteristics and clinical data. *New*  
216 *Microbes New Infect* 3:4-9.
- 217 7. Cuny C, Layer F, Strommenger B, Witte W. 2011. Rare occurrence of methicillin-  
218 resistant *Staphylococcus aureus* CC130 with a novel *mecA* homologue in humans in  
219 Germany. *PLoS One* 6(9): e24360.
- 220 8. Kriegeskorte A, Ballhausen B, Idelevich EA, Köck R, Friedrich AW, Karch H, Peters G,  
221 Becker K. 2012. Human MRSA Isolates with Novel Genetic Homolog, Germany. *Emerg*  
222 *Infect Dis* 18:1016-1018.
- 223 9. Becker K, Ballhausen B, Köck R, Kriegeskorte A. 2014. Methicillin resistance in  
224 *Staphylococcus* isolates: the "mec alphabet" with specific consideration of *mecC*, a *mec*  
225 homolog associated with zoonotic *S. aureus* lineages. *Int J Med Microbiol* 304(7):794-  
226 804.
- 227 10. Becker K, Larsen AR, Skov RL, Paterson GK, Holmes MA, Sabat AJ, Friedrich AW,  
228 Köck R, Peters G, Kriegeskorte A. 2013. Evaluation of a modular multiplex-PCR  
229 methicillin-resistant *Staphylococcus aureus* (MRSA) detection assay adapted for *mecC*  
230 detection. *J Clin Microbiol* 51(6):1917-1919.
- 231 11. Becker K, Denis O, Roisin S, Mellmann A, Idelevich EA, Knaack D, van Alen S,  
232 Kriegeskorte A, Köck R, Schaumburg F, Peters G, Ballhausen B. 2016. Detection of  
233 *mecA*- and *mecC*-positive methicillin-resistant *Staphylococcus aureus* (MRSA) isolates  
234 by the new Xpert MRSA Gen 3 PCR assay. *J Clin Microbiol* 54(1):180-184.
- 235 12. Cuny C, Wieler LH, Witte E. 2015. Livestock-Associated MRSA: The Impact on  
236 Humans. *Antibiotics* 4(4): 521-543.
- 237 13. Cuny C, Pasemann B, Witte W. 1999. Detection of Oxacillin Resistance in  
238 *Staphylococcus aureus* by Screening Tests. *Eur J Clin Microbiol Infect Dis* 18:834-836.

- 239 14. Paterson GK, Harrison EM, Holmes MA. 2014. The emergence of *mecC* methicillin-  
240 resistant *Staphylococcus aureus*. Trends Microbiol 22(1):42-47.
- 241 15. Cartwright EJP, Paterson GK, Raven KE, Harrison EM, Gouliouris T, Kearns A, Pichon  
242 B, Edwards G, Skov RL, Larsen AR, Holmes MA, Parkhill J, Peacock SJ, Török ME.  
243 2013. Use of Vitek 2 Antimicrobial Susceptibility Profile To Identify *mecC* in  
244 Methicillin-Resistant *Staphylococcus aureus*. J Clin Microbiol 51(8):2732-2734.
- 245 16. Skov R, Larsen AR, Kearns A, Holmes M, Teale C, Edwards G, Hill R. 2014.  
246 Phenotypic detection of *mecC*-MRSA: cefoxitin is more reliable than oxacillin. J  
247 Antimicrob Chemother 69(1):133-135.

248 Table 1: Susceptibility pattern testing cefoxitin and oxacillin for *mecC*-positive *S. aureus*  
 249 isolates (n = 111)

Cefoxitin/oxacillin susceptibility pattern <sup>a</sup>	Number and (% agreement) of isolates tested by <sup>b</sup>		
	Phoenix	MicroScan WalkAway	Vitek 2
R/R	11 (9.9 %)	5 (4.5 %)	9 (8.1 %)
R/S	60 (54.1 %)	103 (92.8 %)	93 (83.8 %)
S/R	1 (0.9 %)	0 (0.0 %)	0 (0.0 %)
Total R <sup>c</sup>	72 (64.9 %)	108 (97.3 %)	102 (91.9 %)
S/S	39 (35.1 %)	3 (2.7 %)	9 (8.1 %)

250

251 <sup>a</sup> R, resistant; S, susceptible;

252 <sup>b</sup> *S. aureus* ATCC 29213 (MSSA) and *S. aureus* ATCC 43300 (MRSA) were used as quality  
 253 control strains. Both were correctly categorized by all three systems;

254 <sup>c</sup> Positive agreement based on resistance to at least one of the compounds tested (cefoxitin or  
 255 oxacillin).

256 Table 2: Growth on selective chromogenic agar media

Chromogenic agar <sup>a</sup>	Number of isolates (n) and (% agreement) with		
	Normal growth <sup>b</sup>	Reduced growth <sup>c</sup>	No growth
Brilliance™ MRSA 2	111 (100 %)	0 (0.0 %)	0 (0.0 %)
chromID® MRSA	111 (100 %)	0 (0.0 %)	0 (0.0 %)
BBL™ CHROMagar® MRSA II	101 (91.0 %)	10 (9.0 %)	0 (0.0 %)
MRSA Select™	105 (94.6 %)	6 (5.4 %)	0 (0.0 %)
CHROMagar™ MRSA	99 (89.2 %)	12 (10.8 %)	0 (0.0 %)

257

258 <sup>a</sup> *S. aureus* ATCC 29213 (MSSA) and *S. aureus* ATCC 43300 (MRSA) were used as quality  
259 control strains;

260 <sup>b</sup> According to the respective manufacturer's instructions;

261 <sup>c</sup> Colonies with smaller size, but with color change as indicated for MRSA.